Journal of Shanghai Jiao Tong University (Medical Science) ›› 2022, Vol. 42 ›› Issue (3): 259-266.doi: 10.3969/j.issn.1674-8115.2022.03.001

• Management of chronic cardiovascular and cerebrovascular diseases colum •     Next Articles

Plasma metabolic signature of cardiovascular and cerebrovascular diseases from a large cohort study

ZHANG Mengji1,2,3(), HUANG Lin4(), LI Zheng1, MA Zhuoran1, WEI Lin1, YUAN Ancai1, HU Liuhua1, ZHANG Wei1, QIAN Kun1,2,3, PU Jun1()   

  1. 1.Department of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
    2.School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China
    3.Institute of Medical Robotics, Shanghai Jiao Tong University, Shanghai 200240, China
    4.Department of Clinical Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
  • Received:2022-01-22 Online:2022-03-28 Published:2022-05-09
  • Contact: PU Jun E-mail:zmj_xy@sjtu.edu.cn;linhuang@shsmu.edu.cn。;pujun310@hotmail.com
  • Supported by:
    National Key R&D Program of China(2018YFC1312800);National Natural Science Foundation of China(82001985);Natural Science Foundation of Shanghai(20ZR1440000);Joint Project of Health Committee of Pudong New Area(PW2019D-11)

Abstract: Objective

·To explore the metabolic differences for the occurrence and development of cardiovascular and cerebrovascular diseases, the study performed the plasma metabolic analysis by nano-enhanced laser desorption ionization-mass spectrometry (NELDI-MS) on a large cohort.

Methods

·People were enrolled from general population establishment and follow-up cohort in Pudong New Area, Shanghai. Plasma samples were prospectively collected from 14 419 cohort people who met the criteria from February to August 2019. All the cohort people were divided into coronary heart disease (CHD) group (n=1 608), stroke group (n=461), cardiovascular and cerebrovascular diseases (CHD+stroke) group (n=145) and the control group (n=12 205). The plasma metabolic fingerprints (PMFs) of the enrolled samples were collected by NELDI-MS and then analyzed by statistical analysis for identifying the typical metabolic biomakers in patients with stroke, patients with CHD, and patients with both CHD and stroke.

Results

·Three hundred and forty-five metabolic signal peaks were extracted as PMFs. Six metabolic biomarkers with differential regulations were identified as the potential risk factor for cardiovascular and cerebrovascular diseases respectively by mass spectrometry data analysis. Further, the six metabolic biomarkers were mapped into the altered ketone body and fatty acid metabolism clusters. In the cluster of ketone body metabolism, the intensities of amidosulfonic acid, acetoacetic acid and methylmalonic acid were significantly increased in patients with CHD, but significantly decreased in patients with stroke and cardiovascular cerebrovascular diseases. In the cluster of fatty acid metabolism, the intensities of glucose, galacturonic acid and α-linolenic acid were significantly decreased in patients with cardiovascular and cerebrovascular diseases, but significantly increased in patients with stroke. According to the above six metabolic biomakers, three related metabolic pathways were identified in the cluster of ketone body metabolism, and two related metabolic pathways were identified in the cluster of fatty acid metabolism.

Conclusion

·The novel solid-phase MS approach used in this study has realized the high-efficiency collection of PMFs in a large cohort of people. Six plasma metabolic biomarkers with differential regulation are identified in cohort people with cardiovascular and cerebrovascular diseases, shedding light on the molecular pathological mechanisms of cardiovascular and cerebrovascular diseases from metabolic perspectives. It is expected to provide metabolic clues for the pathogenesis of cardiovascular and cerebrovascular diseases.

Key words: cardiovascular and cerebrovascular disease, coronary heart disease (CHD), stroke, plasma metabolic fingerprint (PMF), metabolomics, biomaker

CLC Number: